Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

NATIONAL INSTITUTE OF TOXICOLOGY, PLLC

NPI: 1558766501 · MOUNT AIRY, NC 27030 · Clinical Medical Laboratory · NPI assigned 11/01/2014

$3.12M
Total Medicaid Paid
53,378
Total Claims
34,153
Beneficiaries
9
Codes Billed
2018-01
First Month
2023-08
Last Month

Provider Details

Authorized OfficialCOX, ERICA (OFFICE ADMINISTRATOR)
NPI Enumeration Date11/01/2014

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 3,073 $264K
2019 21,277 $1.23M
2020 13,107 $813K
2021 8,264 $447K
2022 5,664 $283K
2023 1,993 $83K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 15,613 10,012 $1.58M
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 16,855 10,754 $1.06M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 7,947 4,698 $311K
99205 Prolong outpt/office vis 522 396 $70K
80305 8,576 5,976 $61K
99406 3,537 2,042 $21K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 146 120 $8K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 141 122 $5K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 41 33 $3K